- Home
- RFL vs VRCA Comparison
RFL vs VRCA Comparison
Compare RFL & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- VRCA
- Stock Information
- Founded
- RFL 2017
- VRCA 2013
- Country
- RFL United States
- VRCA United States
- Employees
- RFL N/A
- VRCA N/A
- Industry
- RFL Real Estate
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- VRCA Health Care
- Exchange
- RFL Nasdaq
- VRCA Nasdaq
- Market Cap
- RFL 54.4M
- VRCA 58.7M
- IPO Year
- RFL N/A
- VRCA 2018
- Fundamental
- Price
- RFL $1.34
- VRCA $4.75
- Analyst Decision
- RFL
- VRCA Hold
- Analyst Count
- RFL 0
- VRCA 5
- Target Price
- RFL N/A
- VRCA $60.00
- AVG Volume (30 Days)
- RFL 110.9K
- VRCA 35.5K
- Earning Date
- RFL 11-05-2025
- VRCA 11-03-2025
- Dividend Yield
- RFL N/A
- VRCA N/A
- EPS Growth
- RFL N/A
- VRCA N/A
- EPS
- RFL N/A
- VRCA N/A
- Revenue
- RFL $732,000.00
- VRCA $14,704,000.00
- Revenue This Year
- RFL N/A
- VRCA $264.34
- Revenue Next Year
- RFL N/A
- VRCA $33.95
- P/E Ratio
- RFL N/A
- VRCA N/A
- Revenue Growth
- RFL 35.56
- VRCA 5.72
- 52 Week Low
- RFL $1.28
- VRCA $3.82
- 52 Week High
- RFL $3.19
- VRCA $20.60
- Technical
- Relative Strength Index (RSI)
- RFL 38.86
- VRCA 31.51
- Support Level
- RFL $1.30
- VRCA $4.87
- Resistance Level
- RFL $1.51
- VRCA $5.20
- Average True Range (ATR)
- RFL 0.11
- VRCA 0.36
- MACD
- RFL -0.00
- VRCA -0.04
- Stochastic Oscillator
- RFL 12.90
- VRCA 0.57
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.